Home › Calculator › HCM Dividend Calculator 2026
HCM Dividend DRIP Calculator 2026
18.59% YieldHealthcareHUTCHMED (China) Limited · NASDAQ
Price: $10.76 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When HCM pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your HCM snowball 📈
$10,000 in HCM → $10.19M in 10 years · $186.75/month
About HUTCHMED (China) Limited (HCM) — Dividend Analysis 2026
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a range of other gastrointestinal and solid tumors. Furthermore, the company's portfolio includes Surufatinib, an inhibitor applicable to numerous conditions such as neuroendocrine tumors (NETs - both pancreatic and non-pancreatic), biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, gastric cancer (GC), thyroid cancer, endometrial cancer (EMC), NSCLC, and general solid tumors. HMPL-523, a spleen tyrosine kinase inhibitor, is designed to treat hematological cancers and specific chronic immune conditions, while HMPL-689 targets the isoform PI3Kd (phosphoinositide 3'-kinase delta). Additional compounds in development include Tazemetostat, an EZH2 inhibitor indicated for specific epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor showing promise for hematological malignancies, gliomas, and solid tumors; HMPL-760, which functions as a Bruton's tyrosine kinase inhibitor; and HMPL-453, an inhibitor aimed at intrahepatic cholangiocarcinoma. The pipeline also features HMPL-295 for solid tumors, HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors, alongside Epitinib (HMPL-813) and Theliatinib (HMPL-309), both of which act as inhibitors. HUTCHMED maintains strategic collaboration agreements with a number of partners, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The entity, established in 2000 and headquartered in Central, Hong Kong, was previously identified as Hutchison China MediTech Limited before officially adopting its current name, HUTCHMED (China) Limited, in May 2021.
Compare HCM with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full HCM DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open HCM position with:
🌍 HCM Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold HCM.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 18.59% | 15.79% | $1,859 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 15.80% | 13.00% | $1,580 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 14.87% | 12.07% | $1,487 / yr |
| 🇬🇧 UK ISA | 0% | 18.59% | 15.79% | $1,859 / yr |
| 🇬🇧 UK Taxable | 8.75% | 16.96% | 14.16% | $1,696 / yr |
| 🇨🇦 TFSA | 0% | 18.59% | 15.79% | $1,859 / yr |
| 🇨🇦 CA Taxable | 25% | 13.94% | 11.14% | $1,394 / yr |
| 🇦🇺 Super (pension) | 15% | 15.80% | 13.00% | $1,580 / yr |
| 🇦🇺 AU Taxable | 30% | 13.01% | 10.21% | $1,301 / yr |
| 🇩🇪 DE Taxable | 26.375% | 13.69% | 10.89% | $1,369 / yr |
| 🇫🇷 FR Taxable | 30% | 13.01% | 10.21% | $1,301 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 HCM Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 HCM Dividend Payment Schedule
HCM pays quarterly — 4 times per year. Next ex-div: TBD.
📊 HCM vs Healthcare Benchmarks
How HCM compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for HCM sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ HCM Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| J-Other | 2026-05-20 | 30,157 | — | — | ||
| J-Other | 2026-05-20 | 26,307 | — | — | ||
| J-Other | 2026-05-20 | 7,644 | — | — | ||
| J-Other | 2026-05-20 | 7,445 | — | — | ||
| J-Other | 2026-05-20 | 132,864 | — | — | ||
| J-Other | 2026-05-20 | 75,140 | — | — | ||
| J-Other | 2026-05-20 | 8,863 | — | — | ||
| J-Other | 2026-05-20 | 5,176 | — | — | ||
| Other | 2023-06-05 | 4,520 | $12.51 | $56.5K | ||
| Other | 2019-12-11 | 400,000 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where HCM earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the HCM dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
HUTCHMED (China) Limited (HCM) is currently trading at $10.76, 75% below its 52-week high. The current dividend yield is 18.59% based on an annual payout of $2.00 per share.
HCM (HUTCHMED (China) Limited) — 18.59% Dividend Yield Analysis
HUTCHMED (China) Limited (HCM) is a healthcare stock currently trading at $10.76 with a dividend yield of 18.59%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (18.59%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest HCM News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.